Figure 3
From: miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer
miR-181d promotes CRC cell glycolysis. (a) Following indicated treatment, ECAR was measured by the Glycolysis Stress test in CRC cell lines. And the glycolysis under basal conditions, the glycolytic capacity, and the glycolytic reserve were analyzed. (b and c) Lactate production in CRC cells transfected with anti-miR-181d or miR-181d mimics was measured by lactate assay. (d) Forced expression of miR-181d increased the consumption of glucose while the knockdown of miR-181d had an opposite effect
